Necrotising Enterocolitis Market Size
Market Size in USD Bn
CAGR5.8%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 5.8% |
| Market Concentration | High |
| Major Players | AbbVie, AstraZeneca, Baxter International, Bristol-Myers Squibb, Fresenius Kabi and Among Others |
please let us know !
Necrotising Enterocolitis Market Analysis
The Global Necrotising Enterocolitis Market is estimated to be valued at USD 7.51 Billion in 2025 and is expected to reach USD 11.14 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. Necrotising enterocolitis is a gastrointestinal disease primarily affecting premature infants. The increasing number of premature births and the subsequently rising incidence of NEC is a major driver for market growth.
Key factors boosting the demand for NEC treatment and management options include growing awareness among patients and care providers, rising per capita healthcare expenditure in developing nations, and increasing investment by leading market players in developing novel treatment alternatives. Moreover, the rising availability of advanced parenteral nutrition and therapeutics for managing NEC complications is also helping to drive the overall market size over the forecast period.